STOCK TITAN
  1. Home
  2. News
  3. NXL

Nexalin Tech (NXL) Stock News

NXL Nasdaq

Welcome to our dedicated page for Nexalin Tech news (Ticker: NXL), a resource for investors and traders seeking the latest updates and insights on Nexalin Tech stock.

Nexalin Technology, Inc. develops non-invasive neurostimulation products based on Deep Intracranial Frequency Stimulation, or DIFS™, for brain-health and mental-health indications. Company news commonly covers peer-reviewed clinical publications, neuroimaging and biomarker data, and research programs addressing insomnia, depression, traumatic brain injury, PTSD, Alzheimer’s disease, dementia-related cognitive decline and ADHD.

Updates also describe the HALO™ Clarity device, the NeuroCare® virtual clinic platform, collaborations with clinical research and academic organizations, FDA engagement, and capital-market communications tied to its Nasdaq-listed common stock.

News

Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.98%
Tags
none
-
News

Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.89%
Tags
none
-
News

Nexalin Technology Unveils Next-Generation HALO™ Clarity

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.67%
Tags
none
News

Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.63%
Tags
clinical trial
-
News

Nexalin Technology Announces Formation of New Military & Government Advisory Board to be Led by Government Affairs Veteran David Lasseter

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.3%
Tags
management
-
News

Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.8%
Tags
clinical trial
News

Nexalin’s CEO Mark White to be Interviewed Live on “The Big Biz Show” Today at 3PM Eastern Time

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.82%
Tags
none
-
News

Nexalin Technology Announces New Public Sector Division to Capitalize on Opportunities to Serve U.S. Government Agencies

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.94%
Tags
none
-
News

Nexalin Technology Announces Abstract Accepted for Presentation at 2023 Military Health System Research Symposium Validating the Potential of its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Mild Traumatic Brain Injury

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.06%
Tags
none
News

Nexalin Technology, Inc. and Wider Come Limited Announce Joint Venture Agreement to Advance Commercialization of Nexalin’s tACS Devices in the Asia Pacific Region

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.24%
Tags
none

FAQ

What is the current stock price of Nexalin Tech (NXL)?

The current stock price of Nexalin Tech (NXL) is $0.4044 as of June 15, 2026.

What is the market cap of Nexalin Tech (NXL)?

The market cap of Nexalin Tech (NXL) is approximately 9.3M.